Stay updated with breaking news from Affect Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- LifeArc Ventures, which is committed to investing in innovative early-stage life science companies, today provides an update on its portfolio....
The region’s venture capital numbers fell a little bit from the previous quarter, but are on par with overall growth from the year.
The Healthtech Times is a weekly newsletter covering healthtech news from Canada and around the globe.
Affect Therapeutics' $16 million Series A funding round was led by ARTIS Ventures and included participation from AlleyCorp, CityLight, LifeArc Ventures, Samsung Next and What If Ventures. In total, Affect Therapeutics has raised about $26 million, said Kristin Muhlner, co-founder and CEO of the company.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!